Vimarsana
Biggest News Aggregation in the World

Page 5 - Colitis Organization News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Colitis Organization. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Colitis Organization Today - Breaking & Trending Today

Immunic, Inc. Reports First Quarter 2022 Financial Results and Provides Corporate Update - Vimarsana News

Immunic, Inc. Reports First Quarter 2022 Financial Results and Provides Corporate Update

/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused...

AbbVie Reports First-Quarter 2022 Financial Results - Vimarsana News

AbbVie Reports First-Quarter 2022 Financial Results

Reports First-Quarter Diluted EPS of $2.51 on a GAAP Basis, an Increase of 26.1 Percent; Adjusted Diluted EPS of $3.16, an Increase of 9.3 Percent; These...

AbbVie Reports First-Quarter 2022 Financial Results - Vimarsana News

AbbVie Reports First-Quarter 2022 Financial Results

Reports First-Quarter Diluted EPS of $2.51 on a GAAP Basis, an Increase of 26.1 Percent; Adjusted Diluted EPS of $3.16, an Increase of 9.3 Percent; These...

Mesoblast Limited (MESO) Q1 2022 Earnings Call Transcript - Vimarsana News

Mesoblast Limited (MESO) Q1 2022 Earnings Call Transcript

MESO earnings call for the period ending December 31, 2021.

Source: fool.com
Switching Study Concludes That Transition From Humira To Samsung Bioepis's Adalimumab Biosimilar Is Safe And Effective - Food, Drugs, Healthcare, Life Sciences - Vimarsana News

Switching Study Concludes That Transition From Humira To Samsung Bioepis's Adalimumab Biosimilar Is Safe And Effective - Food, Drugs, Healthcare, Life Sciences

Results of the PROPER study, an interim analysis assessing the safety and efficacy of switching from Abbvie's Humira to Samsung Bioepsis's biosimilar adalimumab product...

Source: mondaq.com